Q2 EPS Estimates for TG Therapeutics Increased by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - HC Wainwright increased their Q2 2026 EPS estimates for shares of TG Therapeutics in a report released on Wednesday, May 6th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings per share of $0.36 for the quarter, up from their previous forecast of $0.20. HC Wainwright has a "Buy" rating and a $70.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $1.34 per share. HC Wainwright also issued estimates for TG Therapeutics' Q3 2026 earnings at $0.42 EPS, Q4 2026 earnings at $0.41 EPS, FY2026 earnings at $1.30 EPS, FY2027 earnings at $2.45 EPS, FY2028 earnings at $3.38 EPS, FY2029 earnings at $3.92 EPS and FY2030 earnings at $4.88 EPS.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of TG Therapeutics from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, May 1st. Zacks Research downgraded shares of TG Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Friday, May 1st. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a "neutral" rating in a research note on Thursday, January 15th. Wall Street Zen downgraded shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Finally, JPMorgan Chase & Co. dropped their price target on shares of TG Therapeutics from $49.00 to $46.00 and set an "overweight" rating for the company in a research note on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $52.50.

TG Therapeutics Trading Up 2.5%

Shares of TGTX stock opened at $43.03 on Friday. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $44.00. The company has a market capitalization of $6.59 billion, a P/E ratio of 15.05 and a beta of 1.68. The firm has a 50-day moving average price of $32.72 and a 200 day moving average price of $31.60. The company has a quick ratio of 3.29, a current ratio of 4.10 and a debt-to-equity ratio of 0.38.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 91.89%. The firm had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. During the same period in the prior year, the business earned $0.03 earnings per share. The company's revenue for the quarter was up 69.5% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Danske Bank A S acquired a new position in shares of TG Therapeutics in the third quarter valued at approximately $25,000. Optiver Holding B.V. boosted its holdings in shares of TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 732 shares during the period. Bessemer Group Inc. boosted its holdings in shares of TG Therapeutics by 117.1% in the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 486 shares during the period. Stone House Investment Management LLC acquired a new position in shares of TG Therapeutics in the third quarter valued at approximately $36,000. Finally, Hantz Financial Services Inc. boosted its holdings in shares of TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 560 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

Key Headlines Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Company raised full‑year 2026 revenue guidance to about $925M and raised U.S. BRIUMVI net product revenue guidance to $885–900M — the stronger outlook is driving optimism about growth and cashflow. TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Q1 revenue jumped ~70% YoY to roughly $205M, driven mainly by strong BRIUMVI U.S. net sales — revenue beat/acceleration supports the higher full‑year target. TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
• Positive Sentiment: Retail momentum and bullish commentary pushed shares to a fresh 52‑week high despite the EPS miss — heightened retail interest can amplify short‑term upside. TGTX stock hits fresh 52-week high – here's why retail is bullish despite Q1 earnings miss
• Neutral Sentiment: Company hosted a conference call and released the Q1 transcript; management reiterated the BRIUMVI rollout progress and guided top‑line metrics — useful for modeling but no material changes to guidance beyond the raise. TG Therapeutics (TGTX) Q1 2026 Earnings Transcript
• Negative Sentiment: Reported EPS came in below consensus (~$0.23) — company-reported EPS was cited around $0.12 (some outlets show $0.17), which disappointed estimates and could limit multiple expansion until sustained profitability visibility continues. TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.